GVAG
ABBV icon

Great Valley Advisor Group’s AbbVie ABBV Stock Holding History

Great Valley Advisor Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.1M Buy
78,399
+7,089
+10% +$1.57M 0.31% 84
2025
Q4 		$16.3M Sell
71,310
-3,462
-5% -$789K 0.31% 82
2025
Q3 		$17.3M Sell
74,772
-3,809
-5% -$776K 0.35% 76
2025
Q2 		$14.6M Sell
78,581
-3,546
-4% -$659K 0.32% 82
2025
Q1 		$17.2M Sell
82,127
-2,003
-2% -$389K 0.37% 67
2024
Q4 		$14.9M Buy
84,130
+1,254
+2% +$231K 0.33% 80
2024
Q3 		$16.4M Buy
82,876
+1,661
+2% +$310K 0.4% 68
2024
Q2 		$13.9M Buy
81,215
+9,270
+13% +$1.54M 0.39% 70
2024
Q1 		$13.1M Buy
71,945
+8,407
+13% +$1.45M 0.4% 68
2023
Q4 		$9.85M Buy
63,538
+1,936
+3% +$282K 0.35% 71
2023
Q3 		$9.18M Buy
61,602
+5,159
+9% +$757K 0.38% 69
2023
Q2 		$7.6M Buy
56,443
+6,225
+12% +$913K 0.32% 79
2023
Q1 		$8M Buy
50,218
+8,360
+20% +$1.28M 0.37% 68
2022
Q4 		$6.76M Sell
41,858
-537
-1% -$82.3K 0.35% 73
2022
Q3 		$5.69M Sell
42,395
-2,379
-5% -$341K 0.32% 78
2022
Q2 		$6.86M Buy
44,774
+5,922
+15% +$905K 0.38% 66
2022
Q1 		$5.92M Buy
38,852
+1,231
+3% +$179K 0.35% 77
2021
Q4 		$4.73M Sell
37,621
-181
-0.5% -$21.4K 0.29% 91
2021
Q3 		$4.08M Buy
37,802
+859
+2% +$98.2K 0.28% 92
2021
Q2 		$4.11M Buy
36,943
+5,320
+17% +$599K 0.3% 84
2021
Q1 		$3.42M Buy
31,623
+9,170
+41% +$981K 0.33% 72
2020
Q4 		$2.41M Sell
22,453
-267
-1% -$25.7K 0.25% 91
2020
Q3 		$1.99M Buy
22,720
+1,820
+9% +$171K 0.24% 94
2020
Q2 		$2.05M Buy
20,900
+3,602
+21% +$317K 0.34% 81
2020
Q1 		$1.32M Buy
17,298
+2,192
+15% +$187K 0.35% 87
2019
Q4 		$1.34M Sell
15,106
-1,868
-11% -$155K 0.3% 103
2019
Q3 		$1.28M Buy
16,974
+422
+3% +$28.9K 0.31% 95
2019
Q2 		$1.2M Sell
16,552
-4,036
-20% -$317K 0.3% 99
2019
Q1 		$1.66M Buy
20,588
+1,238
+6% +$101K 0.53% 50
2018
Q4 		$1.75M Buy
+19,350
New +$1.7M 0.66% 34

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Great Valley Advisor Group's ABBV Position: Q1 2026 in Review

Great Valley Advisor Group increased its AbbVie (ABBV) stake by 9.9% in Q1 2026, buying an estimated $1.57M and bringing the position to 78,399 shares worth $17.1M. The position accounts for 0.31% of the portfolio, ranked #84.

Great Valley Advisor Group first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $17.3M in Q3 2025. 4,087 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Great Valley Advisor Group held 78,399 shares of AbbVie worth $17.1M as of Q1 2026.
  • Great Valley Advisor Group bought 7,089 AbbVie shares in Q1 2026, an estimated $1.57M.
  • AbbVie made up 0.31% of Great Valley Advisor Group's portfolio in Q1 2026, its #84 holding.
  • Great Valley Advisor Group first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Great Valley Advisor Group's AbbVie position peaked at $17.3M in Q3 2025.
  • 4,087 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Great Valley Advisor Group's 13F filing for Q1 2026, filed 11 May 2026.